Cost-Effectiveness between Double and Single Fecal Immunochemical Test(s) in a Mass Colorectal Cancer Screening
Table 3
Odds ratio (OR) and 95% confidence interval (CI) of detection of advanced neoplasm using colonoscopy as a gold standard by gender, age group, and fecal immunochemical test (FIT) status in the Jiashan mass colorectal cancer screening program in China, 2007–2009.
Gender
Age
FIT
Colonoscopy participant
Advanced neoplasm
OR1 (95% CI)
OR2 (95% CI)
OR3 (95% CI )
(%)
Men
<55
FIT1
182
23 (12.6)
1.0
1.0
FIT2
162
15 (9.3)
0.71 (0.35–1.40)
1.0
1.0
Both
54
11 (20.4)
1.77 (0.80–3.91)
2.51 (1.07–5.86)
1.0
Either
294
27 (9.2)
0.70 (0.39–1.26)
0.99 (0.51–1.92)
1.0
Men
≥55
FIT1
245
42 (17.1)
1.0
1.43 (0.83–2.48)
FIT2
196
28 (14.3)
0.81 (0.48–1.36)
1.0
1.63 (0.84–3.18)
Both
73
20 (27.4)
1.82 (0.99–3.37)
2.26 (1.18–4.34)
1.48 (0.64–3.41)
Either
368
50 (13.6)
0.76 (0.49–1.19)
0.94 (0.57–1.55)
1.56 (0.95–2.55)
Women
<55
FIT1
257
11 (4.3)
1.0
1.0
FIT2
198
7 (3.5)
0.82 (0.31–2.15)
1.0
1.0
Both
57
4 (7.0)
1.69 (0.52–5.51)
2.06 (0.59–7.30)
1.0
Either
398
14 (3.5)
0.82 (0.36–1.83)
1.0 (0.40–2.51)
1.0
Women
≥55
FIT1
237
27 (11.4)
1.0
2.88 (1.39–5.94)
FIT2
198
22 (11.1)
0.97 (0.54–1.77)
1.0
3.41 (1.42–8.18)
Both
66
13 (19.7)
1.91 (0.92–3.95)
1.96 (0.93–4.16)
3.25 (1.00–10.61)
Either
369
36 (9.8)
0.84 (0.50–1.43)
0.87 (0.49–1.52)
2.97 (1.57–5.59)
Men
All
FIT1
432
65 (15.0)
1.0
1.0
FIT2
358
43 (12.0)
0.77 (0.51–1.17)
1.0
1.0
Both
127
31 (24.4)
1.82 (1.13–2.96)
2.34 (1.41–3.96)
1.0
Either
663
77 (11.6)
0.74 (0.52–1.06)
0.96 (0.65–1.43)
1.0
Women
All
FIT1
494
38 (7.7)
1.0
0.47 (0.31–0.72)
FIT2
396
29 (7.3)
0.95 (0.57–1.57)
1.0
0.58 (0.35–0.95)
Both
123
17 (11.4)
1.93 (1.05–3.54)
2.03 (1.07–3.84)
0.50 (0.26–0.95)
Either
767
56 (7.3)
0.95 (0.62–1.45)
1.00 (0.63–1.59)
0.60 (0.42–0.86)
Both
All
FIT1
926
103 (11.1)
1.0
—
FIT2
754
72 (9.5)
0.84 (0.61–1.16)
1.0
—
Both
250
48 (19.2)
1.90 (1.30–2.76)
2.25 (1.51–3.35)
—
Either
1,430
127 (8.9)
0.78 (0.59–1.02)
0.92 (0.68–1.25)
—
FIT1, the first FIT; FIT2, the second FIT; OR1 using FIT1 as reference and OR2 using FIT2 as reference; OR3 using men with age <55 who completed FIT1 as reference, OR3 using men with age <55 who completed FIT2 as reference, OR3 using men with age <55 who completed both FIT1 and FIT2 as reference, OR3 using men with age <55 who completed either FIT1 or FIT2 as reference, OR3 using women with age <55 who completed FIT1 as reference, OR3 using women with age <55 who completed FIT2 as reference, OR3 using women with age <55 who completed both FIT1 and FIT2 as reference, and OR3 using women with age <55 who completed either FIT1 or FIT2 as reference.
